Eli Lilly announced a $3 billion manufacturing site in Katwijk, the Netherlands, to produce its oral GLP‑1 candidate orforglipron and other medicines. The plant expands Lilly’s European production footprint amid surging demand for obesity and metabolic therapeutics and is intended to scale supply for oral and small‑molecule programs. The investment underscores drugmakers’ push to bring manufacturing closer to key markets and to secure capacity for high‑volume, chronic therapies.